Evolocumab: all 105 studies that test it
Page 1 of 2. Open to participants first (14), then studies with results posted, then the rest; newest registration first within each.
- RESCUE: PCSK9 Inhibitors for Carotid Vulnerable Plaque RemodelingNot yet recruitingNCT07819643Phase 4
- A Trial Assessing the Effectiveness of Evolocumab in Reducing the Plaque Burden in Participants With Subclinical AtheromaNot yet recruitingNCT07803679Phase 4
- CAPRA-EVO: a Randomized Serial PCCT Trial of Early Evolocumab After ACSRecruitingNCT07612774Phase 4
- Adding Evolocumab to Conventional Lipid-lowering Therapy for Hypertriglyceridemia Induced Acute PancreatitisRecruitingNCT07388420Not applicable
- Effects of PCSK-9 Inhibitor Treatment Prior to Undergoing Primary Percutaneous Coronary Intervention in Patients With ST-segment Elevation Myocardial InfarctionRecruitingNCT06364124Not applicable
- Studies to Gain Insight How the Drugs PCSK9-inhibitors and Statins Affect Cholesterol and Bile Acid MetabolismNot yet recruitingNCT06140095Early Phase 1
- Mechanistic Clinical Trial of PCSK9 Inhibition for AAANot yet recruitingNCT06081153Early Phase 1
- Study on the Composite Endpoint Event of PCSK9 Inhibitor in Patients With Very High Risk of ASCVD and CancerNot yet recruitingNCT05976893Phase 4
- Evolocumab Added to Statin Therapy in Symptomatic Intracranial Atherosclerotic Stenosis (EAST-ICAS)RecruitingNCT05741086Phase 3
- Cholesterol Lowering and Residual Risk in Diabetes, Type 1RecruitingNCT05641753Phase 4
- Intensive Lipid-lowering in Patients With STEMI and NSTEMI (Germany on Target)Not yet recruitingNCT05587621Not applicable
- High-Resolution Assessment of Extracranial Plaques in a Multiple Centers Evolocumab Randomized StudyRecruitingNCT05585151Phase 4
- The Impact of Pcsk-9 Inhibition on PET CFR in Patients at High CV RiskRecruitingNCT05152888Phase 4
- Impact of Evolocumab as an Additional Lipid-lowering Therapy to Changes in Lipid Core Burden Index of Non-culprit Vulnerable Plaque in Patients Who Underwent Percutaneous Coronary Intervention for the Acute Coronary SyndromeRecruitingNCT04719221Phase 4
- A Randomized Pilot Study of Evolocumab Plus Nivolumab/Ipilimumab in Treatment-Naïve Patients With Metastatic NSCLCTerminatedNCT05144529Phase 2Results posted
- Effect of Evolocumab on Coronary Plaque CharacteristicsCompletedNCT04710368Phase 4Results posted
- Lipid Management in Renal Transplant Recipients Using Evolocumab.CompletedNCT04608474Phase 4Results posted
- Reducing Intracranial atheroSclErosis With RepathaTerminatedNCT04573777Phase 4Results posted
- Pharmacodynamic Biomarkers to Support Biosimilar Development: PCSK9 InhibitorsCompletedNCT04189484Phase 1Results posted
- Evolocumab in Patients With Acute MICompletedNCT04082442Phase 2Results posted
- Impact of Evolocumab in Cardiac Transplant Patients With CAVCompletedNCT03944577Phase 2Results posted
- Effect of Evolocumab in Patients at High Cardiovascular Risk Without Prior Myocardial Infarction or StrokeCompletedNCT03872401Phase 3Results posted
- The Effects of Evolocumab in Patients With Diabetes and Atherosclerotic Vascular DiseaseCompletedNCT03829046Phase 4Results posted
- Effect of Evolocumab on Coronary AtherosclerosisCompletedNCT03689946Phase 3Results posted
- Imaging of Coronary Plaques in Participants Treated With EvolocumabCompletedNCT03570697Phase 3Results posted
- Evolocumab in Acute Coronary SyndromeCompletedNCT03515304Phase 2Results posted
- Effect of Evolocumab on Coronary Endothelial FunctionCompletedNCT03500302Phase 2Results posted
- Safety and Efficacy of Evolocumab in Addition to Optimal Stable Background Statin Therapy in Chinese Participants With Primary Hypercholesterolemia and Mixed DyslipidemiaTerminatedNCT03433755Phase 3Results posted
- Safety and Tolerability of Repatha® (Evolocumab) in Indian Participants With Homozygous Familial HypercholesterolemiaCompletedNCT03403374Phase 4Results posted
- A Study Of Multiple Immunotherapy-Based Treatment Combinations In Participants With Metastatic Non-Small Cell Lung Cancer (Morpheus- Non-Small Cell Lung Cancer)TerminatedNCT03337698Phase 1/2Results posted
- Impact of LDL-cholesterol Lowering on Platelet ActivationTerminatedNCT03331666Phase 4Results posted
- Effects of Evolocumab on Platelet Reactivity in Patients With Diabetes MellitusTerminatedNCT03258281Phase 4Results posted
- Impact of Evolocumab on the Effects of Clopidogrel in Patients With High On-Treatment Platelet ReactivityCompletedNCT03096288Phase 4Results posted
- Fourier Open-label Extension Study in Subjects With Clinically Evident Cardiovascular Disease in Selected European CountriesTerminatedNCT03080935Phase 3Results posted
- Effects of PCSK9 Inhibition by Evolocumab on Postprandial Lipid Metabolism in Type 2 DiabetesCompletedNCT02948777Phase 4Results posted
- Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk Open-label ExtensionCompletedNCT02867813Phase 3Results posted
- Safety, Tolerability and Efficacy on Low Density Lipoprotein Cholesterol (LDL-C) of Evolocumab in Participants With Human Immunodeficiency Virus (HIV) and Hyperlipidemia/Mixed DyslipidemiaCompletedNCT02833844Phase 3Results posted
- Evaluation of Evolocumab (AMG 145) Efficacy in Diabetic Adults With Hypercholesterolemia/Mixed DyslipidemiaCompletedNCT02739984Phase 3Results posted
- Effects of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibition on Arterial Wall Inflammation in Patients With Elevated Lipoprotein(a) (Lp(a))CompletedNCT02729025Phase 3Results posted
- Safety and Efficacy of Evolocumab in Combination With Statin Therapy in Adults With Diabetes and Hyperlipidemia or Mixed DyslipidemiaCompletedNCT02662569Phase 3Results posted
- Safety, Tolerability and Efficacy of Evolocumab (AMG 145) in Children With Inherited Elevated Low-density Lipoprotein Cholesterol (Familial Hypercholesterolemia)CompletedNCT02624869Phase 3Results posted
- Trial Assessing Efficacy, Safety and Tolerability of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibition in Paediatric Subjects With Genetic Low-Density Lipoprotein (LDL) DisordersCompletedNCT02392559Phase 3Results posted
- Open-label Extension (OLE) Study to Assess Safety and Efficacy of EvolocumabCompletedNCT02304484Phase 3Results posted
- Estimation Study to Assess the Effect of Severe Renal Impairment and End-stage Renal Disease Hemodialysis on the Pharmacokinetics of EvolocumabCompletedNCT02275156Phase 1Results posted
- Evaluating PCSK9 Binding antiBody Influence oN coGnitive HeAlth in High cardiovascUlar Risk SubjectsCompletedNCT02207634Phase 3Results posted
- Effects on Lipoprotein Metabolism From PCSK9 Inhibition Utilizing a Monoclonal AntibodyCompletedNCT02189837Phase 3Results posted
- Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin Intolerant Subjects-3CompletedNCT01984424Phase 3Results posted
- Study of Low-Density Lipoprotein Cholesterol (LDL-C) Reduction Using Evolocumab (AMG 145) in Japanese Patients With Advanced Cardiovascular RiskCompletedNCT01953328Phase 3Results posted
- Study to Assess in Home Use of Evolocumab (AMG 145) Administration Using Either an Automated Mini-doser or a Prefilled Autoinjector/PenCompletedNCT01879319Phase 3Results posted
- Open-label Extension Study of Evolocumab (AMG 145) in Adults With Hyperlipidemia and Mixed DyslipidemiaCompletedNCT01854918Phase 3Results posted
- Study to Assess In-home Use of Evolocumab (AMG 145) Using a Prefilled Syringe or a Prefilled Autoinjector/PenCompletedNCT01849497Phase 3Results posted
- GLobal Assessment of Plaque reGression With a PCSK9 antibOdy as Measured by intraVascular UltrasoundCompletedNCT01813422Phase 3Results posted
- Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated RiskCompletedNCT01764633Phase 3Results posted
- Reduction of LDL-C With PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder Study-2CompletedNCT01763918Phase 3Results posted
- Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin Intolerant Subjects -2CompletedNCT01763905Phase 3Results posted
- LDL-C Assessment With PCSK9 Monoclonal Antibody Inhibition Combined With Statin Therapy-2CompletedNCT01763866Phase 3Results posted
- Monoclonal Antibody Against PCSK9 to Reduce Elevated LDL-C in Subjects Currently Not Receiving Drug Therapy for Easing Lipid Levels-2CompletedNCT01763827Phase 3Results posted
- A Study to Evaluate Tolerability and Efficacy of Evolocumab (AMG 145) in Japanese SubjectsCompletedNCT01652703Phase 2Results posted
- Trial Assessing Long Term USe of PCSK9 Inhibition in Subjects With Genetic LDL DisordersCompletedNCT01624142Phase 2/3Results posted
- Trial Evaluating PCSK9 Antibody in Subjects With LDL Receptor AbnormalitiesCompletedNCT01588496Phase 2/3Results posted
- Durable Effect of PCSK9 Antibody CompARed wiTh placEbo StudyCompletedNCT01516879Phase 3Results posted
- LAPLACE-TIMI 57: Low-density Lipoprotein Cholesterol (LDL-C) Assessment With PCSK9 monoclonaL Antibody Inhibition Combined With Statin thErapyCompletedNCT01380730Phase 2Results posted
- Monoclonal Antibody Against PCSK9 to Reduce Elevated Low-density Lipoprotein Cholesterol (LDL-C) in Adults Currently Not Receiving Drug Therapy for Easing Lipid LevelsCompletedNCT01375777Phase 2Results posted
- Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin Intolerant SubjectsCompletedNCT01375764Phase 2Results posted
- Reduction of Low-Density Lipoprotein Cholesterol (LDL-C) With PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder StudyCompletedNCT01375751Phase 2Results posted
- Ascending Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Evolocumab (AMG 145) in Adults With Hyperlipidemia on Stable Doses of a StatinCompletedNCT01133522Phase 1Results posted
- Comparing the Extent to Which Two Evolocumab Drug Products Are Made Available in the Body After a Single Subcutaneous Dose.CompletedNCT07545226Phase 1
- Comparing the Extent to Which Two Evolocumab Drug Products Are Made Available in the Body After a Single Subcutaneous DoseCompletedNCT07422285Phase 1
- Early Administration of PCSK9 Inhibitors After Thrombectomy for Atherosclerotic Acute Ischemic Stroke: A Randomized Controlled TrialCompletedNCT07295366Phase 4
- A Phase II Study Bolstering Outcomes by Optimizing Immunotherapy Strategies With Evolocumab and Nivolumab in Patients With Metastatic Renal Cell Carcinoma (BOOST-RCC)Active, not recruitingNCT06284564Phase 2
- Expression of Pro- and Anti-inflammatory Cytokines During Anti-PCSK9 in Familial HypercholesterolemiaCompletedNCT06231459Phase 4
- Evolocumab in STEMIActive, not recruitingNCT06081803Phase 3
- Safety and Efficacy of Evolocumab in Ischemic StrokeStatus unknownNCT05697185Phase 4
- Effect of Early Initiation of Evolocumab on Lipid Profiles Changes in Patients With ACS Undergoing PCICompletedNCT05661552Phase 4
- Effect of Very Early and Rapid Lowering Cholesterol With Evolocumab on Left Ventricular Remodeling in Patients With Anterior STEMI Undergoing Primary PCITerminatedNCT05613426Phase 4
- The Safety and Long-Term Clinical Benefit of PCSK9i in STEMI PatientsStatus unknownNCT05579418Phase 4
- EVOLVE-MI: EVOLocumab Very Early After Myocardial InfarctionActive, not recruitingNCT05284747Phase 4
- Evolocumab or Normal Strategies to Reach LDL Objectives in Acute Myocardial Infarction Upbound to PCIActive, not recruitingNCT04951856Phase 4
- Impact of PCSK9 Inhibition on Clinical Outcome in Patients During the Inflammatory Stage of the COVID-19CompletedNCT04941105Phase 3
- The PCSK9i Inhibitor Evolocumab - a Surgical Trial of Pharamcodynamics and Kinetics EvaluationCompletedNCT04937413Early Phase 1
- CARotid plaqUe StabilizatiOn and Regression With Evolocumab.Status unknownNCT04730973Phase 4
- PCSK 9 Inhibition as Secondary Prevention in Renal Transplant PatientsCompletedNCT04665830Phase 3
- Evolocumab Plus Ezetimibe in Haemodialized Statin-intolerant Patients With HypercholesterolemiaStatus unknownNCT04659525Phase 4
- Markers of Cardiovascular Risk in Patients With Premature Coronary Artery Disease and TreatmentStatus unknownNCT04613167Not applicable
- A Study of Evolocumab on Carotid Artery Atherosclerotic Plaque Morphology Prior to Carotid EndArterectomyStatus unknownNCT04539223Phase 4
- Evolocumab In Advanced Chronic Kidney Disease TrialWithdrawnNCT04510844Phase 4
- Evolocumab Plus Ezetimibe in High Risk Haemodialized Statin Intolerant PatientsStatus unknownNCT04397653Phase 4
- Impact of PCSK9 Inhibitors on Coronary Microvascular Dysfunction in Patients With Atherosclerotic Cardiovascular Disease Proved by Myocardial Ischemia and Needing CoronarographyStatus unknownNCT04338165Phase 2
- Effect of Evolocumab in Patients With Critical Limb Ischemia (Evol-CLI)Status unknownNCT04306471Phase 4
- Effect of Evolocumab in Functional Status and LDL Oxidation of Patients With Peripheral Arterial DiseaseStatus unknownNCT04306081Phase 4
- Early Treatment With Evolocumab in Patients With ST-elevation Myocardial InfarctionWithdrawnNCT04303377Phase 2
- Functional Improvement of Coronary Artery Narrowing by Cholesterol Reduction With a PCSK9 AntibodyCompletedNCT04141579Not applicable
- PCSK9 Inhibitor Treatment for Patients With SPG5Status unknownNCT04101643Phase 1/2
- Effect of Evolocumab Added to Moderate-Intensity Statin Therapy on LDL-C Lowering and Cardiovascular Adverse Events in Patients With Acute Coronary SyndromeStatus unknownNCT04100434Phase 4
- The CHORAL Flow StudyTerminatedNCT04073134Phase 4
- EXpanded Combination of Evolocumab Plus Empagliflozin on Diabetes: EXCEED-BHS3 TrialCompletedNCT03932721Phase 4
- Effect of Evolocumab on Carotid Plaque Composition in Asymptomatic Carotid Artery Stenosis (EVOCAR-1)Status unknownNCT03931161Phase 4
- Effect of Evolocumab on Saphenous Vein Graft Patency Following Coronary Artery Bypass SurgeryCompletedNCT03900026Phase 4
- Evolocumab for PCSK9 Lowering in Early Acute Sepsis (The PLEASe Study)Status unknownNCT03869073Phase 2
- Multislice Computed Tomography Assessment of PCSK9 Inhibition on Coronary PerfusionWithdrawnNCT03851263Phase 4